Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Cytarabine
Related studies linked through entity extraction aliases.
VEN+IDAC vs IDAC in AML
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2/PHASE3
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
- Status
- WITHDRAWN
- Phase
- PHASE1
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
ALL Backbone in AYAs
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- Status
- RECRUITING
- Phase
- PHASE3
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
- Status
- RECRUITING
- Phase
- PHASE3
MRD-positive AML Clinical Study
- Status
- RECRUITING
- Phase
- NA
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
- Status
- RECRUITING
- Phase
- PHASE2